Trulieve Cannabis
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 days.
- Its last 4 Sell calls were actually followed by a +22% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is +33.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 2.0% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation C
How expensive the stock is versus earnings, sales and its own 5-year history.
| Forward P/E | 31.1x | Better than 17% |
| Price / Sales | 1.9x | Better than 58% |
Growth C+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | -1.0% | Better than 21% |
| Net income CAGR (3Y) | 18.3% | Better than 71% |
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 60.2% | Better than 75% |
| Operating margin | 12.6% | Better than 58% |
| Net margin | -9.9% | Better than 16% |
| Return on equity | -9.6% | Better than 20% |
| Return on invested capital | -4.2% | Better than 23% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -21.8% | Better than 28% |
| 6-month return | 15.7% | Better than 78% |
| 12-month return (ex latest month) | 93.7% | Better than 94% |
| Distance below 52-week high | 34.6% | Better than 35% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.4x | Better than 83% |
| Debt to assets | 20.9% | Better than 55% |
| Interest coverage | 2.4x | Better than 40% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 107.4% | Better than 85% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 9.35
- Open
- 9.24
- Day range
- 8.68 - 9.42
- Avg price
- 8.90
- Volume
- 1.71M
- Turnover
- 15.24M
- Turnover ratei
- 1.18%
- Volume ratioi
- 1.15
- Amplitudei
- 7.91%
- 52-week rangei
- 5.00 - 13.28
Valuation
- P/Ei
- -14.23
- P/E (TTM)i
- -3.76
- P/Bi
- 2.17
- EPSi
- -0.61
- Book value / shi
- 4.00
- Net profit
- -117.75M
- Net assets
- 771.57M
Share structure
- Market cap
- 1.68B
- Float capi
- 1.26B
- Shares out
- 193.04M
- Float sharesi
- 145.20M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
34.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-6.04M net over the window
Short interest
- Shares short
- 3.84M
- % of floati
- 2.00%
- Days to coveri
- 3.37
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Trulieve Cannabis (TRLV)?
Trulieve Cannabis last traded at 8.68. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Trulieve Cannabis's market cap?
About 1.68B.
What is the P/E ratio of Trulieve Cannabis?
The trailing twelve-month P/E is -3.76, below its own 5-year average of 0.66 — in the middle of its historical range (35.44% percentile). See the Valuation tab for the full history.
Does Trulieve Cannabis pay a dividend?
Trulieve Cannabis does not currently pay a regular dividend.
Is Trulieve Cannabis a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 18.00, which implies 107.4% upside from the current price. This is not investment advice.
What is Trulieve Cannabis's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Trulieve Cannabis a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:55:00 · For reference only, not investment advice and not tailored to your situation.
Trulieve Cannabis discussion 0 comments